Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.67, for a total transaction of $1,167,000.00. Following the transaction, the insider now directly owns 1,098,499 shares in the company, valued at $12,819,483.33. This trade represents a 8.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, December 10th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.16, for a total value of $1,316,000.00.
• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.88, for a total transaction of $1,488,000.00.

ARS Pharmaceuticals Stock Up 3.3 %

SPRY stock traded up $0.36 during trading on Thursday, reaching $11.32. The stock had a trading volume of 1,268,100 shares, compared to its average volume of 832,676. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -22.20 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a one year low of $5.02 and a one year high of $18.51. The company's 50 day moving average is $14.44 and its two-hundred day moving average is $12.42.

Analyst Ratings Changes

A number of research analysts have weighed in on SPRY shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Leerink Partners lifted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a research note on Friday, September 20th. Finally, William Blair upgraded ARS Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $24.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. J.W. Cole Advisors Inc. increased its position in ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company's stock worth $131,000 after buying an additional 1,500 shares during the last quarter. nVerses Capital LLC bought a new stake in ARS Pharmaceuticals in the 3rd quarter valued at about $30,000. Creative Planning lifted its holdings in ARS Pharmaceuticals by 7.0% during the third quarter. Creative Planning now owns 35,263 shares of the company's stock valued at $511,000 after purchasing an additional 2,307 shares during the last quarter. HighTower Advisors LLC boosted its position in ARS Pharmaceuticals by 18.2% during the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company's stock worth $411,000 after purchasing an additional 4,369 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock valued at $63,000 after purchasing an additional 4,472 shares during the period. Institutional investors own 68.16% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.